Cancer vaccine - sigma-tau
Latest Information Update: 31 Dec 2021
Price :
$50 *
At a glance
- Originator sigma-tau SpA
- Class Cancer vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Solid tumours
Most Recent Events
- 05 Mar 2007 Phase-I clinical trials in Solid tumours in Italy (Injection)
- 07 Nov 2006 Preclinical trials in Cancer in Italy (Injection)